MSK-IMPACT Tumor Profiling Test Authorized by FDA

A tumor profiling assay that tests for far more mutations than any other test has received authorization from the US Food and Drug Administration (FDA). The product, developed at the Memorial Sloan Kettering (MSK) Cancer Center in New York City, is known as MSK-IMPACT. MSK’s David Klimstra, Michael Berger, David Solit, Kenneth Offit are quoted.